{"nctId":"NCT00574795","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants","startDateStruct":{"date":"2007-09"},"conditions":["Vaccines, Pneumococcal Conjugate Vaccine"],"count":193,"armGroups":[],"interventions":[{"name":"13vPnC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy 2 to 6 month-old infant\n* Available for entire study period\n\nExclusion Criteria:\n\n* Previous vaccination with licensed or investigational pneumococcal vaccine.\n* Previous anaphylactic reaction to any vaccine or vaccine-related component.\n* Contraindication to vaccination with a pneumococcal conjugate vaccine.\n* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.\n* Known or suspected immune deficiency or suppression.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"6 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series","description":"Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Local Reactions","description":"Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\>7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"19.9","spread":null},{"groupId":"OG002","value":"14.3","spread":null},{"groupId":"OG003","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"53.9","spread":null},{"groupId":"OG003","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"50.3","spread":null},{"groupId":"OG003","value":"44.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"28.7","spread":null},{"groupId":"OG002","value":"29.3","spread":null},{"groupId":"OG003","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"0.7","spread":null},{"groupId":"OG003","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"74.4","spread":null},{"groupId":"OG002","value":"67.8","spread":null},{"groupId":"OG003","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null},{"groupId":"OG001","value":"64.8","spread":null},{"groupId":"OG002","value":"55.6","spread":null},{"groupId":"OG003","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"43.5","spread":null},{"groupId":"OG002","value":"38.9","spread":null},{"groupId":"OG003","value":"40.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"0.7","spread":null},{"groupId":"OG003","value":"1.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events","description":"Systemic events (fever ≥ 37.5 degrees Celsius \\[C\\], fever ≥ 38 C but ≤ 39 C, fever \\>39 C but ≤ 40 C, fever \\> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"33.1","spread":null},{"groupId":"OG002","value":"40.3","spread":null},{"groupId":"OG003","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"12.2","spread":null},{"groupId":"OG002","value":"10.3","spread":null},{"groupId":"OG003","value":"20.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"16.5","spread":null},{"groupId":"OG002","value":"9.7","spread":null},{"groupId":"OG003","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"36.1","spread":null},{"groupId":"OG002","value":"23.5","spread":null},{"groupId":"OG003","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"29.4","spread":null},{"groupId":"OG002","value":"22.2","spread":null},{"groupId":"OG003","value":"24.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"23.1","spread":null},{"groupId":"OG002","value":"15.9","spread":null},{"groupId":"OG003","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"0.7","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"5.5","spread":null},{"groupId":"OG003","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"2.1","spread":null},{"groupId":"OG003","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series","description":"GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose","description":"Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose","description":"GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.97","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":193},"commonTop":["Injection site erythema","Erythema (Any)","Injection site swelling","Erythema (Mild)","Pyrexia"]}}}